Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(2.33)
# 2,603
Out of 5,169 analysts
113
Total ratings
43.43%
Success rate
-1.65%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLNN Clene | Maintains: Buy | $48 | $6.57 | +630.59% | 7 | Mar 13, 2026 | |
| CMPS COMPASS Pathways | Maintains: Buy | $15 → $20 | $5.88 | +240.14% | 5 | Feb 18, 2026 | |
| BIIB Biogen | Maintains: Buy | $220 → $230 | $182.31 | +26.16% | 22 | Feb 9, 2026 | |
| GHRS GH Research | Maintains: Buy | $35 → $39 | $15.02 | +159.65% | 5 | Jan 6, 2026 | |
| STOK Stoke Therapeutics | Maintains: Buy | $28 → $36 | $31.02 | +16.05% | 5 | Jan 5, 2026 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $25 → $24 | $9.55 | +151.31% | 7 | Nov 6, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $160 → $164 | $130.71 | +25.47% | 17 | Oct 29, 2025 | |
| ATAI AtaiBeckley | Maintains: Buy | $11 → $14 | $3.56 | +293.26% | 4 | Oct 22, 2025 | |
| ANVS Annovis Bio | Maintains: Buy | $17 | $2.47 | +588.26% | 4 | Sep 30, 2025 | |
| CRVO CervoMed | Maintains: Buy | $21 → $27 | $4.24 | +536.79% | 6 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $12 | $3.76 | +219.15% | 5 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $112 → $80 | $1.65 | +4,748.48% | 7 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $33 | $20.32 | +62.40% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $150 | $9.09 | +1,550.17% | 4 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $29.61 | - | 2 | Jan 31, 2017 |
Clene
Mar 13, 2026
Maintains: Buy
Price Target: $48
Current: $6.57
Upside: +630.59%
COMPASS Pathways
Feb 18, 2026
Maintains: Buy
Price Target: $15 → $20
Current: $5.88
Upside: +240.14%
Biogen
Feb 9, 2026
Maintains: Buy
Price Target: $220 → $230
Current: $182.31
Upside: +26.16%
GH Research
Jan 6, 2026
Maintains: Buy
Price Target: $35 → $39
Current: $15.02
Upside: +159.65%
Stoke Therapeutics
Jan 5, 2026
Maintains: Buy
Price Target: $28 → $36
Current: $31.02
Upside: +16.05%
Zevra Therapeutics
Nov 6, 2025
Maintains: Buy
Price Target: $25 → $24
Current: $9.55
Upside: +151.31%
Neurocrine Biosciences
Oct 29, 2025
Maintains: Buy
Price Target: $160 → $164
Current: $130.71
Upside: +25.47%
AtaiBeckley
Oct 22, 2025
Maintains: Buy
Price Target: $11 → $14
Current: $3.56
Upside: +293.26%
Annovis Bio
Sep 30, 2025
Maintains: Buy
Price Target: $17
Current: $2.47
Upside: +588.26%
CervoMed
Jul 29, 2025
Maintains: Buy
Price Target: $21 → $27
Current: $4.24
Upside: +536.79%
Mar 13, 2025
Maintains: Buy
Price Target: $14 → $12
Current: $3.76
Upside: +219.15%
Jan 6, 2025
Maintains: Buy
Price Target: $112 → $80
Current: $1.65
Upside: +4,748.48%
Mar 12, 2024
Maintains: Buy
Price Target: $40 → $33
Current: $20.32
Upside: +62.40%
Aug 3, 2021
Maintains: Buy
Price Target: $101 → $150
Current: $9.09
Upside: +1,550.17%
Jan 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $29.61
Upside: -